JCEM: Risk of cardiovascular events in plasma triamine N-oxide serotonin and type 2 diabetes

Although triamcinolone N-oxide (TMAO) has been shown to interfere with the pathophysiology of atherosclerosis and diabetes, the association between TMAO and major adverse cardiovascular events (MACE) in patients with type 2 diabetes (T2D) has not been clearly established, in a recent study published in Journal of The Clinical Endocrinology and Metabolism, the authoritative journal for endocrine and metabolic diseases, researchers explored the relationship between plasma TMAO concentrations and MACE and all-cause mortality in a single-center forward-looking group of continuously recruited T2D patientsparticipants in the SURDIETRIAL trial (58% were male) aged 65 to 10TMAO concentrations were significantly correlated with diabetes, renal function, HDL-cholesterol, sTNFR1 (R2-0.27), and patients treated with metformin increased significantly even after adjusting eGFR: 6.7 (8.5) vs8.5 (13.6) smol/L (adjusted eGFR p.0207)During the follow-up period (median duration (IQR) was 85 (75) months), there were 403 MACE and 538 deathsMacE-free survival and all-cause mortality were significantly associated with a quartile distribution of TMAO concentrations, and patients with the highest TMAO levels had the greatest risk of outcome (p.0001)In the multivariate Cox model, patients with TMAO concentration in the fourth quart had an increased risk of MACE compared to patients with the first three quarts: adjHR was 1.32 (1.02-1.70) ;p .0325Similarly, in multivariate analysis, TMAO was significantly associated with mortality: adjHR was 1.75 (1.17-2.09 ;p);, there is a link between higher TMAO concentrations and macE risk and increased all-cause mortality